Clinical Trials

Date:
Categories:
Clinical Trials, Mesothelioma, Pleural Mesothelioma, Status
Tags:
Comments:
0

Dasatinib in Resectable Malignant Pleural Mesothelioma

Primary Objectives:
The primary objective of this novel phase I trial will be the level of biomarker modulation of p-Src Tyr 419 by induction dasatinib therapy in patients with resectable malignant pleural mesothelioma.
Secondary Objectives:
Secondary objectives include overall and progression-free survival, tumor radiographic and pathologic response, and safety-toxicity profiles. Exploratory analyses will include additional biomarker evaluation in pre- and post-treatment tumor specimens, and serum/platelet/pleural effusion biomarker modulation.
Arms: Dasatinib: Experimental
70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.

Read More »

Date:
Categories:
Clinical Trials, Closed, Lung Cancer, Mesothelioma, Pleural Mesothelioma, Status
Tags:
Comments:
0

N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy (NAC-PNP)

Purpose: In this study we want to investigate the efficacy of N-acetylcysteine (NAC), which is an anti-oxidant, in the prevention of cisplatin-induced neural toxicity, in patients treated for lung cancer with chemotherapy containing cisplatin.

Arm 1: Active Comparator
  • Drug: N-Acetylcysteine.
  • Intervention:
    N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg.
  • Other Name: Fluimucil
Arm 2: Placebo Comparator
  • Drug: Placebo.
  • Intervention: Placebo once every 3 weeks intravenous saline fluid.
  • Other Name: Placebo

Read More »

Date:
Categories:
Clinical Trials, Mesothelioma, Pleural Mesothelioma, Status, Terminated
Tags:
Comments:
0

Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery

Rationale: Immunotoxins can find tumor cells and kill them without harming normal cells. Drugs used in chemotherapy, such as pemetrexed and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with immunotoxin therapy may kill more malignant mesothelioma cells.

Purpose: This phase I trial is studying the side effects and best dose of immunotoxin therapy when given together with pemetrexed and cisplatin in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.

Read More »

Date:
Categories:
Clinical Trials, Mesothelioma, Pleural Mesothelioma, Recruiting, Status
Tags:
Comments:
0

Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Mediastinal or Chest Wall Neoplasms, or Lung Metastases From Cancers of Non-Thoracic Origin

Rationale: Collecting and storing samples of tissue, blood, and urine from patients with cancer to study in the laboratory may help the study of cancer. It may also help doctors identify patients who are eligible for clinical trials.

Purpose: This study is collecting and examining tissue, blood, and urine samples from patients with non-small cell lung cancer, esophageal cancer, malignant pleural mesothelioma, mediastinal or chest wall neoplasms, or lung metastases from cancers of non-thoracic origin.

Read More »

Date:
Categories:
Clinical Trials, Closed, Mesothelioma, Mesothelioma of the Tunica Vaginalis, Peritoneal Mesothelioma, Pleural Mesothelioma, Status
Tags:
Comments:
0

AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Rationale: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Purpose: This phase II trial is studying how well AZD2171 works in treating patients with malignant mesothelioma that cannot be removed by surgery.

Read More »

Date:
Categories:
Clinical Trials, Closed, Mesothelioma, Pleural Mesothelioma, Status
Tags:
Comments:
0

Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma

Purpose: This is a study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug, suberoylanilide hydroxamic acid, in the treatment of advanced malignant pleural mesothelioma.

Arm 1: Vorinostat
Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683)
Vorinostat 300 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
Arm 2: Placebo Comparator
Drug: Comparator: Placebo
Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.

Read More »

Date:
Categories:
Clinical Trials, Closed, Lung Cancer, Mesothelioma, Status
Tags:
Comments:
0

Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

Purpose: Occupational exposure to asbestos is known increase the risk of developing cancer of the lungs (bronchogenic carcinoma) or of the pleura (mesothelioma). Symptoms are subtle and non-specific, diagnosis is often late and the prognosis consequently is dismal. Currently there is no accepted non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects. In the last decade, low-dose computed tomography (LDCT) has been successfully developed and validated for the early diagnosis of lung cancer in high-risk smokers. Malignant mesothelioma might, in an early stage, resemble a benign pleural plaque, which is a common finding after asbestos exposure. We target to develop low-dose CT as a tool to serially image the pleural plaques, quantify their individual and overall volume, compute the growth rate with time, and, as such, identify the presence of mesothelioma early, before symptoms occur.

Read More »